Rabies vaccine - Yisheng Biopharma

Drug Profile

Rabies vaccine - Yisheng Biopharma

Alternative Names: PIKA adjuvant-based rabies vaccine - Yisheng Biopharma; PIKA rabies vaccine - Yisheng Biopharma

Latest Information Update: 06 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yisheng Biopharma
  • Developer Duke-NUS Graduate Medical School Singapore; Yisheng Biopharma
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rabies
  • New Molecular Entity No

Highest Development Phases

  • Phase II Rabies

Most Recent Events

  • 04 Jan 2017 Clinical trials in Rabies in USA (IM)
  • 04 Jan 2017 Rabies vaccine - Yisheng Biopharma receives Orphan Drug status for Rabies in USA
  • 01 Oct 2016 Yisheng Biopharma completes a phase II trial in Rabies (Prevention, In volunteers) in Singapore (IM) (NCT02956421)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top